Azitra clears safety review, moves ATR-04 trial to Cohort 2
The Phase 1/2 study of ATR04-484 for EGFR inhibitor-associated skin rash advances after a safety panel review of six Cohort 1 patients.
SEC filing
Latest
4 stories
Today
Monday, September 28
Azitra files $3.5 million at-the-market stock offering with A.G.P.
The dermatology biotech, whose shares closed at $0.1680, disclosed a new sales agreement and warned its ATR-12 trial pause and NYSE American price risks could persist.
SEC filing
Azitra sets up $3.5 million at-the-market stock sale facility with A.G.P.
Azitra entered a sales agreement on September 28, 2026 allowing it to sell up to $3,503,232 in common stock through A.G.P./Alliance Global Partners over time.
SEC filing
Wednesday, August 12
Azitra reports Q2 2026 results, pauses Netherton syndrome enrollment
Azitra highlighted early ATR-COSF cosmetic data and ATR-04 rash trial progress while pausing further enrollment in its ATR-12 Netherton syndrome study.
SEC filing